Pulmonary Fate of Fluticasone: Challenges Met
Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.
In Vitro System for Orally Inhaled Drug Release
Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
The Role of In Silico Regional Deposition Modelling and Pharmacokinetic Profiling in the Development of a Generic Tiotropium Dry Powder Inhaler
Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.
The influence of blend composition on the aerodynamic performance of a novel high resistance multi-dose device
Explore the study by Irene Rossi on blend composition’s influence on Aptar Prohaler®. Insights into FPM, MMAD, and aerodynamic performance in COPD treatment
In Vitro and In Silico Comparison of Indacaterol and Glycopyrrolate Pulmonary Deposition between a Single-Unit Dose and a Multi-Unit Dry Powder Inhaler
In-depth study by Nanopharm on In Vitro and In Silico comparison of Indacaterol and Glycopyrrolate in single-unit and multi-unit DPIs for COPD treatment.
Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Regional Deposition in Generic Dry Powder Inhalers
Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.
Faster, Cost-Effective Alternative to Generic Bioequivalence
Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.
Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug
Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.
